ASH 2013 - Maintenance Matters
This study confirms again that they are correct - Rd thoroughly trounces MPT.
For those of us seniors with access to Revlimid, though, this study clearly demonstrates the advantage of Revlimid maintenance after initial therapy. It studied 1,623 newly-diagnosed myeloma patients over age 65 or ineligible for transplant, in three study arms: (A) Rd until disease progression; (B) Rd for 72 weeks or progression; and (C) MPT for 72 weeks or progression.
Some results for patients on continuous Rd versus those on 72-week Rd:
Median progression-free survival: 26 months versus 21 months.
Four-year overall survival: 59% versus 51%.
As time goes on, I would expect the difference in survival to grow. If this were me, I sure would want to stay on the Revlimid continuously, rather than leave it after a year and a half.
Oh wait, it IS me! I'm on a study of Pomalyst, in the same family of drugs as Revlimid, and it has kept my cancer under control for five and a half years now. My study initially included low-dose Dex, just like this study, but my Dex was gradually reduced to zero over about 80 weeks. For all practical purposes I have been on maintenance, using Pomalyst as a single agent, for at least four years. During my study I have been able to run 50 marathons, so maintenance has offered a good quality of life.
Source: Myeloma Hope - Category: Cancer Source Type: blogs
More News: Cancer | Cancer & Oncology | Dexamethasone | Myeloma | Prednisone | Revlimid | Stem Cell Therapy | Stem Cells | Study | Transplants | Velcade